依托泊苷|T0132

價(jià)格	￥287	￥430	￥697
包裝	50mg	100mg	200mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:依托泊苷	英文名稱:Etoposide
CAS:33419-42-0	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.95%	產(chǎn)品類別: 抑制劑
貨號(hào): T0132

Product Introduction

Bioactivity

名稱	Etoposide
描述	Etoposide (VP-16-213) is a topoisomerase II inhibitor that inhibits DNA synthesis by forming a complex with topoisomerase II and DNA (IC50=60.3 μM). Etoposide has antitumor activity and induces apoptosis and autophagy.
細(xì)胞實(shí)驗(yàn)	After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells [5].
激酶實(shí)驗(yàn)	Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained [5].
動(dòng)物實(shí)驗(yàn)	The in vivo model for nude mice HB (NMHB) has been established. Only HB cells with embryonal components are grafted and reproduced successfully in this model. Each NMHB subsequently is transplanted into 50 mice for treatment groups. Treatment is initiated when the majority of the tumors reach a volume of 50-100 mm3. The mice are stratified according to their tumor volume and randomly assigned to groups of ten animals each. The animals injected with tumor are given ifosfamide, cisplatin, doxorubicin, etoposide (10 mg/kg/day, i.v.), and carboplatin as single agents in two blocks. One group of ten animals for each original xenograft served as a control group. After initiation of treatment, the tumor growth is recorded at 5-day intervals for 25-30 days and the relative tumor volumes are calculated. Twenty-four hours before the animals are sacrificed, bromodeoxyuridine (BrdU) is injected intraperitoneally for the semiquantitative determination of proliferation activity of the tumor cells (50 μg of BrdU/g body weight) [4].
體外活性	方法：人宮頸癌細(xì)胞 HeLa 用 Etoposide (25-400 μM) 處理 24-48 h，使用 MTT 方法檢測(cè)細(xì)胞活力。結(jié)果：Etoposide 抑制 Hela 細(xì)胞增殖，處理 24 h 和 48 h 的 IC50 分別為 167.3 μM 和 52.7 μM。[1] 方法：人肺腺癌細(xì)胞 A549 用 Etoposide (0.75-3 μM) 處理 4 h，使用 Flow Cytometry 方法檢測(cè)細(xì)胞周期情況。結(jié)果：Etoposide 導(dǎo)致 G0/G1 和 S 期的 A549 細(xì)胞百分比顯著降低。同時(shí)，G2/M 期的細(xì)胞顯著增加。[2] 方法：小鼠胚胎成纖維細(xì)胞 MEFs 用 Etoposide (1.5-150 μM) 處理 3-18 h，使用 Western Blot 方法檢測(cè)靶點(diǎn)蛋白表達(dá)水平。結(jié)果：150?μM的 Etoposide 在 6 h 內(nèi)誘導(dǎo) Caspase-3 的強(qiáng)烈裂解，而 1.5 或 15?μM 僅在 18 h 后激活 Caspase-3。[3]
體內(nèi)活性	方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Etoposide (10 mg/kg) 和 Cisplatin (5-7.5 mg/kg) 腹腔注射給攜帶人子宮內(nèi)膜腺癌腫瘤 Ishikawa 的 KSN nude 小鼠，每?jī)商煲淮?，持續(xù)兩周。結(jié)果：作為單一藥物，Etoposide 對(duì)腫瘤生長(zhǎng)幾乎沒(méi)有抑制作用。Etoposide 和 Cisplatin 聯(lián)合治療顯著抑制腫瘤生長(zhǎng)。[4] 方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Etoposide (80 mg/kg in 0.5% methylcellulose) 灌胃給藥給攜帶人膠質(zhì)母細(xì)胞腫瘤 U87 的免疫缺陷小鼠，每天一次，持續(xù)四十天。結(jié)果：80 mg/kg Etoposide 抑制 U87 腫瘤生長(zhǎng)，抑制率為95%。[5]
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.89 mg/mL (10.01 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. DMSO : 60 mg/mL (101.94 mM)
關(guān)鍵字	P388 \| HCT116 \| p53 \| chemotherapy \| Etoposide \| Mitochondrial Autophagy \| Topoisomerase \| FBXW \| Inhibitor \| anti-cancer \| inhibit \| VP 16 \| Mitophagy \| Bacterial \| Autophagy \| prodrug \| VP16 \| Apoptosis \| leukemia \| Antibiotic
相關(guān)產(chǎn)品	Guanidine hydrochloride \| Naringin \| Doxycycline \| Neomycin sulfate \| Hydroxychloroquine \| Dimethyl sulfoxide \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Ampicillin sodium \| Sulfamethoxazole sodium \| Paeonol \| Kanamycin sulfate
相關(guān)庫(kù)	微生物天然產(chǎn)物庫(kù) \| 抗癌活性化合物庫(kù) \| 抗癌上市藥物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 已知活性化合物庫(kù) \| 中藥單體化合物庫(kù) \| 天然產(chǎn)物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗感染天然產(chǎn)物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字：依托泊苷|||依托泊甙|||VP-16-213|||VP-16|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.2651萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊(cè)資本：566.2651萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫(kù)，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

11-酮基-BETA-乳香酸|TN1182

￥463

辛波莫德|T6403

￥259

消旋山莨菪堿|T0970

￥108